ards: an evidence-based update. by mac sweeney
DESCRIPTION
Rob mac Sweeney dissects the current evidence base that governs our diagnosis and management of ARDS. Distressing results.TRANSCRIPT
![Page 2: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/2.jpg)
Disclosure• Research funding from Northern Ireland Health and Social Care
Research and Development Board• Research into ARDS biomarkers
• http://www.criticalcarereviews.com/index.php/smacc-2014
References
![Page 4: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/4.jpg)
A Condition That….
1. can’t diagnose2. of limited use3. no specific treatment for4. people don’t die from
……….. doesn’t actually exist
![Page 5: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/5.jpg)
Wikimedia Commons
![Page 6: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/6.jpg)
Wikimedia Commons
![Page 7: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/7.jpg)
Wikimedia Commons
![Page 8: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/8.jpg)
Causes
Pulmonary • Pneumonia• Pulmonary contusion• Inhalational injury• Aspiration• Fat embolism• Near Drowning
Extra-Pulmonary • Extra-pulmonary sepsis• Trauma• Burns• Acute Pancreatitis• Massive Transfusion• Drug overdose
![Page 9: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/9.jpg)
Acute Respiratory Distress Syndrome
![Page 10: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/10.jpg)
Acute Respiratory Distress Syndrome
![Page 11: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/11.jpg)
Original Description • Case Series of 12
![Page 12: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/12.jpg)
Original Description • Syndrome of
• Severe Dyspnoea• Tachypnoea• Cyanosis refractory to oxygen therapy• Loss of lung compliance• Benefit with PEEP• Possible benefit with steroids• Diffuse alveolar infiltration
![Page 13: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/13.jpg)
![Page 14: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/14.jpg)
![Page 15: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/15.jpg)
Acute Lung Injury
ALI ARDS
300 – 200 mmHg < 200 mmHg
40 – 26.6 kPa < 40 kPa
![Page 16: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/16.jpg)
![Page 17: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/17.jpg)
Acute Respiratory Distress Syndrome
mild moderate severe
< 300 mmHg < 200 mmHg
< 40 kPa < kPa 26.6
< 100 mmHg
< kPa 13.3
![Page 18: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/18.jpg)
![Page 19: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/19.jpg)
Wikimedia Commons
![Page 20: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/20.jpg)
Definition
Prediction
Clinical Utility
Autopsy Timing
![Page 21: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/21.jpg)
Definition
Prediction
Clinical Utility
Autopsy
Timing Oedema
Timing
![Page 22: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/22.jpg)
Definition
Prediction
Clinical Utility
Autopsy
Timing Oedema PaO2/FiO2
Radiograph InfiltratesOedemaOrigin
![Page 23: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/23.jpg)
Definition
Prediction
Clinical Utility
Autopsy
Timing Oedema PaO2/FiO2
OxygenationOxygenation
![Page 24: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/24.jpg)
Definition
Prediction
Clinical Utility
Autopsy
Timing Oedema PaO2/FiO2
Infiltrates
Infiltrates
Infiltrates
![Page 25: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/25.jpg)
Definition
Utility
Clinical Utility
Autopsy
Timing Oedema PaO2/FiO2
Infiltrates
Infiltrates
![Page 26: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/26.jpg)
Definition
Utility
Clinical Utility
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Temporality
Temporary
Temporality
![Page 27: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/27.jpg)
Definition
Utility
Clinical Utility
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Clinical Use
Temporary Reality
ClinicalReality
![Page 28: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/28.jpg)
Definition
Utility
Clinical Utility
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Temporary
ClinicalConsequence
Recognition
Recognition
Reality
![Page 29: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/29.jpg)
Definition
Utility
Mortality
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Temporary Recognition Reality
![Page 30: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/30.jpg)
Definition
Utility
Mortality
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Temporary
Severity
Cause
Recognition
Cause
Reality
![Page 31: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/31.jpg)
Definition
Utility
Mortality
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Temporary
Severity
Cause Prediction
Recognition
Prediction
Reality
![Page 32: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/32.jpg)
Definition
Utility
Mortality
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Temporary
Severity
Cause Prediction
Recognition Reality
![Page 33: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/33.jpg)
Definition
Utility
Mortality
Autopsy
Timing Oedema PaO2/FiO2 Infiltrates
Temporary
DiffuseAlveolarDamage
Cause Prediction
DAD
Recognition Reality
![Page 34: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/34.jpg)
Source: Wikimedia Commons
![Page 35: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/35.jpg)
50%
![Page 36: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/36.jpg)
50%
![Page 37: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/37.jpg)
One in Two
![Page 38: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/38.jpg)
DAD
ARDS
![Page 39: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/39.jpg)
DAD
ARDS
![Page 40: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/40.jpg)
Pneumonia No Lesion
Abscess
COPD
DAD
ARDS
![Page 41: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/41.jpg)
Pneumonia No Lesion
Abscess
COPD Cancer
DAD
ARDS
![Page 42: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/42.jpg)
Pneumonia No Lesion
Abscess
COPD Cancer
DAD
ARDS
![Page 43: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/43.jpg)
Pneumonia No Lesion
Abscess
COPD Cancer
DAD
ARDS
![Page 44: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/44.jpg)
Pneumonia No Lesion
Abscess
COPD Cancer
DAD
ARDS
![Page 45: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/45.jpg)
Pneumonia No Lesion
Abscess
COPD Cancer
DAD
ARDS
![Page 46: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/46.jpg)
Pneumonia No Lesion
Abscess
COPD Cancer
DADPEBleedingFibrosisPOTB
ARDS
![Page 47: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/47.jpg)
DAD
ARDS
![Page 48: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/48.jpg)
DAD
NON - DAD
ARDS
![Page 49: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/49.jpg)
ARDS
NON - ARDS
![Page 50: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/50.jpg)
ARDS
NON - ARDS
Therapy
General
![Page 51: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/51.jpg)
ARDS
NON - ARDS
Therapy
DADSpecific
![Page 52: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/52.jpg)
![Page 53: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/53.jpg)
ARDS – A Condition That….
1. can’t diagnose (we can’t agree to diagnose)2. of limited use (doesn’t change management)3. no specific treatment for (getting to it)4. people don’t die from (mostly)
5. doesn’t actually exist (half the time)
![Page 54: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/54.jpg)
ARDS – A Condition That….
1. can’t diagnose (we can’t agree to diagnose)2. of limited use (doesn’t change management)3. no specific treatment for (getting to it)4. people don’t die from (mostly)
5. doesn’t actually exist (half the time)
![Page 55: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/55.jpg)
ARDS – A Condition That….
1. can’t diagnose (we can’t agree to diagnose)2. of limited use (doesn’t change management)3. no specific treatment for (getting to it)4. people don’t die from (mostly)
5. doesn’t actually exist (half the time)
![Page 56: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/56.jpg)
ARDS – A Condition That….
1. can’t diagnose (we can’t agree to diagnose)2. of limited use (doesn’t change management)3. no specific treatment for (getting to it)4. people don’t die from (mostly)
5. doesn’t actually exist (half the time)
![Page 57: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/57.jpg)
ARDS – A Condition That….
1. can’t diagnose (we can’t agree to diagnose)2. of limited use (doesn’t change management)3. no specific treatment for (getting to it)4. people don’t die from (mostly)
5. doesn’t actually exist (half the time)
![Page 58: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/58.jpg)
ARDS – A Condition That….
1. can’t diagnose (we can’t agree to diagnose)2. of limited use (doesn’t change management)3. no specific treatment for (getting to it)4. people don’t die from (mostly)
…….doesn’t actually exist (half the time)
![Page 59: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/59.jpg)
?
![Page 60: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/60.jpg)
![Page 61: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/61.jpg)
Therapeutic Evidence-Base
Timing InfiltratesOedema PaO2/FiO2
Temporary Function Clinical
Severity Mortality
DAD
?
![Page 62: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/62.jpg)
Ventilatory Adjuncts
Haemodynamics
Drugs
ECMO
Ventilation
![Page 63: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/63.jpg)
Tidal Volume • 861 ARDS patients (P/F < 300 cm H20)
• 6 ml/kg & Pplt ≤ 30 cm H20 versus
• 12 ml/kg & Pplt ≤ 50 cm H20 • 9% absolute risk reduction in 28 day
mortality
![Page 64: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/64.jpg)
Tidal Volume • 150 critically ill mechanically
ventilated patients
• 6 ml/kg vs 10 ml/kg
Development of ARDS• 2.6% versus 13.5%; p = 0.01
![Page 65: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/65.jpg)
Tidal Volume • 400 patients undergoing major
abdominal surgery
• 10-12 ml/kg & ZEEP & no recruitment versus• 6-8 ml/kg & PEEP 6-8 cm H20 & RM
• Postoperative Respiratory Support• 5% vs 17% • RR 0.29 (95% CI 0.14 to 0.61)
![Page 66: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/66.jpg)
Oscillate
• 548 ARDS patients • PaO2/FiO2 < 200 cmH20• Fi02 > 0.5
In-hospital mortality • HFOV 47% vs Control 35% (RR 1.33; 95% CI 1.09 to 1.64; P = 0.005)
![Page 67: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/67.jpg)
Oscar
• 548 ARDS patients • PaO2/FiO2 < 200 cmH20• PEEP > 5 cmH20
30 day mortality• HFOV 41.7% vs Control 41.1%• Difference 0.6%, 95% CI −6.1 to 7.5
![Page 68: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/68.jpg)
Haemodynamics
Drugs
ECMO
Ventilation
![Page 69: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/69.jpg)
Ventilatory Adjuncts
Haemodynamics
Drugs
ECMO
Ventilation
![Page 70: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/70.jpg)
ACURASYS Study
• 340 ARDS patients• PaO2/FiO2 < 150 mmHg
Adjusted Mortality at Day 90 • NMB: 31.6% vs placebo: 40.7%• HR 0.68 (95% CI 0.48 to 0.98; P = 0.04)
![Page 71: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/71.jpg)
PROSEVA Study
• 466 ARDS patients • PaO2/FiO2 < 150 cmH20
28 day mortality• Prone: 16% vs Control 32.8%
Unadjusted 90-day mortality• Prone: 23.6% vs supine 41.0%
![Page 72: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/72.jpg)
Prone Ventilation
• 4 RCTS• 1,573 patients
In the most hypoxaemic• 486 patients• PaO2/FiO2 < 100 mmHg• absolute mortality reduction 10%
(6% to 21%)
![Page 73: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/73.jpg)
Ventilatory Adjuncts
NMBs
Drugs
ECMO
Ventilation
Prone
![Page 74: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/74.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 75: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/75.jpg)
FACTT Study
• 1000 patients with ALI• 0 ml vs 7000 ml fluid balance at day 7
60 Day Mortality• Conservative: 25.5% vs liberal 28.4%
95% CI difference −2.6 to 8.4 %, P=0.3
![Page 76: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/76.jpg)
FACTT Study
• 1000 patients with ALI• 0 ml vs 7000 ml fluid balance at day 7
60 Day Mortality• Conservative: 25.5% vs liberal 28.4%
95% CI difference −2.6 to 8.4 %, P=0.3
![Page 77: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/77.jpg)
FACTT Study
• 1000 patients with ALI• 0 ml vs 7000 ml fluid balance at day 7
60 Day Mortality• Conservative: 25.5% vs liberal 28.4%
95% CI difference −2.6 to 8.4 %, P=0.3
![Page 78: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/78.jpg)
Ventilatory Adjuncts
Fluids
Fluids CVC
ECMO
Ventilation
![Page 79: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/79.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 80: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/80.jpg)
Drugs
![Page 81: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/81.jpg)
Drugs
Clinically Tested1. NMBs √2. Steroids ?3. Surfactant X4. β2 agonists X5. Diuretics ?6. Ketoconazole X7. Activated Protein C X8. Nitric Oxide X9. Silvelestat X10. Lisofylline X11. Pharmaconutrients X
![Page 82: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/82.jpg)
Drugs
Clinically Tested1. NMBs √2. Steroids ?3. Surfactant X4. β2 agonists X5. Diuretics ?6. Ketoconazole X7. Activated Protein C X8. Nitric Oxide X9. Silvelestat X10. Lisofylline X11. Pharmaconutrients X
Clinically Untested1. Prostacyclin2. Almitrine3. Ibuprofen4. N-Acetylcysteine5. Mucolytics6. Albumin
![Page 83: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/83.jpg)
Drugs
Clinically Tested1. NMBs √2. Steroids ?3. Surfactant X4. β2 agonists X5. Diuretics ?6. Ketoconazole X7. Activated Protein C X8. Nitric Oxide X9. Silvelestat X10. Lisofylline X11. Pharmaconutrients X
Clinically Untested1. Prostacyclin2. Almitrine3. Ibuprofen4. N-Acetylcysteine5. Mucolytics6. Albumin
Next Wave1. Statins2. Aspirin3. ACEI / ARB4. Macrolides5. Insulin6. Vitamin D7. Antibodies• Complement• Interleukins
8. Stem cells9. Growth factors10. Gene therapy
![Page 84: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/84.jpg)
Drugs
Clinically Tested1. NMBs √2. Steroids ?3. Surfactant X4. β2 agonists X5. Diuretics ?6. Ketoconazole X7. Activated Protein C X8. Nitric Oxide X9. Silvelestat X10. Lisofylline X11. Pharmaconutrients X
Clinically Untested1. Prostacyclin2. Almitrine3. Ibuprofen4. N-Acetylcysteine5. Mucolytics6. Albumin
Next Wave1. Statins2. Aspirin3. ACEI / ARB4. Macrolides5. Insulin6. Vitamin D7. Antibodies• Complement• Interleukins
8. Stem cells9. Growth factors10. Gene therapy
![Page 85: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/85.jpg)
ALTA Study
• 282 patients with ALI• Aerosolized albuterol vs saline
Ventilator-free days • albuterol 14.4 vs control 16.6 d• 95% CI difference –4.7 to 0.3 d; P =
0.087Hospital death • albuterol 23.0% vs control 17.7%• 95% CI difference –4.0 to 14.7%, P=0.30
![Page 86: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/86.jpg)
BALTI 2 Study
• 326 ARDS patients • PaO2/FiO2 < 200 mmHg
• IV salbutamol vs placebo
28 day mortality• salbutamol: 34% vs Control 23%• RR 1 47, 95% CI 1 03 to 2 08∙ ∙ ∙
![Page 87: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/87.jpg)
Nitric Oxide
Severe ARDS • n = 329, six trials• RR 1.01; 95% CI 0.78 to 1.32; p = 0.93
Mild to Moderate ARDS• n = 740, seven trials• RR1.12, 95% CI 0.89 to 1.42; p = 0.33
![Page 88: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/88.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 89: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/89.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 90: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/90.jpg)
ECMO
CESAR STUDY• 170 patients with severe respiratory
failure
6 month mortality outcome• ECMO centre 63% vs referral 47%• RR 0·69; 95% CI 0·05 to 0·97, p=0·03
![Page 91: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/91.jpg)
ECMO
ANZICS H1N1 ECMO Case Series• 2009 influenza A(H1N1) - associated
ARDS• 68 patients
• Median PaO2/FiO2 56 (48-63) mmHg• 71% survival
![Page 92: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/92.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 93: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/93.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 94: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/94.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 95: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/95.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 96: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/96.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 97: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/97.jpg)
Ventilatory Adjuncts
Fluids
Drugs
ECMO
Ventilation
![Page 98: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/98.jpg)
To Summarise
1. The positive studies would likely be positive in any critical care condition
2. The negative studies are probably negative because they have been studied in any critical care condition (i.e. ARDS) rather than the specific condition that they are intended for (i.e. DAD)
![Page 99: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/99.jpg)
To Summarise
1. The positive studies would likely be positive in any critical care condition
2. The negative studies may be negative because they have been studied in any critical care condition (i.e. ARDS) rather than the specific condition that they are intended for (i.e. DAD)
![Page 100: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/100.jpg)
To Summarise
1. The positive studies would likely be positive in any critical care condition
2. The negative studies may be negative because they have been studied in any critical care condition (i.e. ARDS) rather than the specific condition that they are intended for (i.e. DAD)
![Page 101: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/101.jpg)
To Summarise
1. The positive studies would likely be positive in any critical care condition
2. The negative studies may be negative because they have been studied in any critical care condition (i.e. ARDS) rather than the specific condition that they are intended for (i.e. DAD)
![Page 102: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/102.jpg)
ARDS – A Condition That….
1. can’t diagnose2. of limited use3. no specific treatment for4. people don’t die from
…….doesn’t actually exist
![Page 103: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/103.jpg)
Final Thoughts
1. ARDS studies need to be able to identify alveolar injury
2. Did the AECCC prevent us from adequately investigating some therapies?
3. Are critical care syndromes really of any use?
![Page 104: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/104.jpg)
http://www.flickr.com/photos/furlined/6744550629
![Page 105: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/105.jpg)
References at: www.criticalcarereviews.com/SMACC
![Page 106: ARDS: An Evidence-based Update. By Mac Sweeney](https://reader038.vdocuments.mx/reader038/viewer/2022103017/556bcd09d8b42a15608b4f99/html5/thumbnails/106.jpg)
Autopsy Case Series
• 712 Autopsies
• 356 ARDS patients
• 159 had DAD (45%)
• 75% of severe ARDS had DAD